{"i": ["NSI - 189", "benzylpiperizine - aminiopyridine", "antidepressant medication", "benzylpiperizine", "antidepressant medication ( s )", "sagittal T1 - weighted , three - dimensional , non - contrast enhanced , inversion recovery high - resolution spiral imaging ( IR - SPGR ) sequence", "placebo", "NSI - 189 phosphate", "NSI 189 phosphate"], "o": ["well tolerated", "safety , PK and PD", "hippocampal volume", "cognitive symptoms", "EEG", "Symptoms Of Depression Questionnaire ( SDQ ), Montgomery - Asberg Depression Scale ( MADRS ), Clinical Global Impressions \u2014 Improvement ( CGI - I ),", "frequency of blood draws", "safety , pharmacokinetics ( PK ) and efficacy .", "Plasma levels", "A1AT and apolipoprotein C3", "total clearance of", "alpha - 1 - antitrypsin ( A1AT ), apolipoprotein C3 ( ApoC3 ), brain - derived neurotrophic factor , cortisol , epidermal growth factor , myeloperoxidase , prolactin , resistin , soluble tumor necrosis factor receptor type 2 , and thyroid stimulating hormone ).", "safety EEG", "CGI - I , MADRS , SDQ , CPFQ and hippocampal and amygdala volumes", "Mean time to maximal peak concentration ( Tmax )", "left hippocampal volume", "self - rating scales", "seizure activity", "depressive symptoms", "serious adverse effects .", "Hippocampal and amygdala volume measurements", "Cmax and area under the curve ( AUC", "hippocampal and amygdala volume", "plasma levels of brain - derived neurotrophic factor , epidermal growth factor , myeloperoxidase , tumor necrosis factor receptor type 2 and A1AT", "( CL / F )", "depressive and cognitive symptoms", "AUCs", "Full profiles", "Pharmacokinetic parameters", "plasma concentrations", "high - frequency alpha", "antidepressant effects", "plasma concentrations of NSI", "pharmacokinetic", "MADRS scores", "clinician - rated MADRS", "neurogenesis in the dentate gyrus", "overall drug exposure", "Massachusetts General Hospital ( MGH ) Cognitive and Physical Functioning Questionnaire ( CPFQ )", "MADRS score", "T1 \u2044 2", "Cmax", "peak - related adverse events ( AEs ).", "Montgomery - Asberg Depression Rating Scale ( MADRS", "Biomarker levels", "tolerated", "depressive symptoms and quantitative electroencephalogram ( qEEG )", "symptoms", "sharp activity", "adverse events", "biomarker levels"]}